|
1
|
Allgayer H, Babic R, Gruetzner KU,
Tarabichi A, Schildberg FW and Heiss MM: C-erbB-2 is of independent
prognostic relevance in gastric cancer and is associated with the
expression of tumor-associated protease systems. J Clin Oncol.
18:2201–2209. 2000.PubMed/NCBI
|
|
2
|
Zhang X, Silva E, Gershenson D and Hung
MC: Amplification and rearrangement of c-erb B proto-oncogenes in
cancer of human female genital tract. Oncogene. 4:985–989.
1989.PubMed/NCBI
|
|
3
|
Yokota J, Yamamoto T, Toyoshima K, et al:
Amplification of c-erbB-2 oncogene in human adenocarcinomas in
vivo. Lancet. 8484:765–767. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hall PA, Hughcs CM, Staddon SL, Richman
PI, Gullick WJ and Lemoine NR: The c-erbB-2 proto-oncogene in
pancreatic cancer. J Pathol. 161:195–200. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D’Emilia J, Bulovas K, D’Ercole K, Wolf B,
Steele G Jr and Summerhayes IC: Expression of the c-erbB-2 gene
product (185) at different stages of neoplastic progression in the
colon. Oncogene. 4:1233–1239. 1989.PubMed/NCBI
|
|
6
|
Tan M, Yao J and Yu D: Overexpression of
the c-erbB-2 gene enhanced intrinsic metastasis potential in human
breast cancer cells without increasing their transformation
abilities. Cancer Res. 57:1199–1205. 1997.
|
|
7
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geyer C, Forster, Lindquist D, et al:
Lapatinib plus capecitabine for HER2-positive advanced breast
cancer. N Engl J Med. 355:2733–2743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for HER2-positive advanced gastric or
gastro-esophageal junction cancer (ToGA): a phase 3, open-label,
randomized controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
|
|
10
|
Green LD, Mack L and Pasieka JL:
Anaplastic thyroid cancer and primary thyroid lymphoma: A review of
these rare thyroid malignancies. J Surg Oncol. 94:725–736. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gilliland FD, Hunt WC, Morris DM and Key
CR: Prognostic factors for thyroid carcinoma: a population-based
study of 15,698 cases from the Surveillance, Epidemiology and End
Results (SEER) program 1973–1991. Cancer. 79:564–573.
1997.PubMed/NCBI
|
|
12
|
Sherman SI: Thyroid carcinoma. Lancet.
361:501–5011. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cohen E, Rosen L, Vokes EE, et al:
Axitinib is an active treatment for all histologic subtypes of
advanced thyroid cancer: Results from a phase II study. J Clin
Oncol. 26:4708–4713. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gupta-Abramson V, Troxel A, Nellore A, et
al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin
Oncol. 26:4714–4719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lemoine NK, Wyllie FS, Lillehaug JR, et
al: Absence of abnormalities of the c-erbB-1 and c-erbB-2
proto-oncogenes in human thyroid neoplasia. Eur J Cancer.
26:777–779. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haugen DR, Akslen LA, Varhaug JE and
Lillehaug JR: Expression of c-erbB-2 protein in papillary thyroid
carcinomas. Br J Cancer. 65:832–837. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hedinger C, Williams ED and Sobin LH: The
WHO histological classification of thyroid tumors: a commentary on
the second edition. Cancer. 63:908–911. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
UICC. International Union Against Cancer:
TNM Classification of Malignant Tumours. 6th edition. John Wiley
& Sons, Inc; New York: pp. 131–141. 2002
|
|
19
|
Kremser R, Obrist P, Spizzo G, et al:
Her2/neu overexpression in differentiated thyroid carcinomas
predicts metastatic disease. Virchows Arch. 442:322–328.
2003.PubMed/NCBI
|
|
20
|
Utrilla JC, Martin-Lacave I, San Martin
MV, Fernandez-Santos JM and Galera-Davidson H: Expression of
c-erbB-2 oncoprotein in human thyroid tumours. Histopathology.
34:60–65. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sugg SL, Ezzat S, Zheng L, Rosen IB,
Freeman JL and Asa SL: Cytoplasmic staining of erbB-2 but not mRNA
levels correlates with differentiation in human thyroid neoplasia.
Clin Endocrinol. 49:629–637. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Potter CR, Van Daele S, Van de Vijver
MJ, et al: The expression of the neu oncogene product in breast
lesions and in normal fetal and adult human tissues.
Histopathology. 15:351–362. 1989.PubMed/NCBI
|
|
23
|
Coombs LM, Pigott DA, Sweeney E, et al:
Amplification and overexpression of c-erbB-2 in transitional cell
carcinoma of the urinary bladder. Br J Cancer. 63:601–608. 1991.
View Article : Google Scholar : PubMed/NCBI
|
